scholarly journals Efficacy of locally endoscopic cytoreductive surgery in elderly patients with advanced gastric cancer

2016 ◽  
Vol 24 (28) ◽  
pp. 3991
Author(s):  
Zhao-Yan Li ◽  
Jian-Feng Gu ◽  
Wei Ding ◽  
Su-Juan Xi ◽  
Hai-Yan Yue ◽  
...  
2014 ◽  
Vol 25 ◽  
pp. ii39
Author(s):  
Iwasa Satoru ◽  
Hamaguchi Tetsuya ◽  
Nagashima Kengo ◽  
Goto Masahiro ◽  
Okazaki Shunsuke ◽  
...  

2021 ◽  
Author(s):  
Omer Yalkin ◽  
Nidal Iflazoglu ◽  
Olgun Deniz ◽  
Mustafa Yener Uzunoglu ◽  
Ezgi Isil Turhan

Abstract Objective: The aim of this study was to clarify the prognostic value of the pathological lymph node ratio for elderly and non-elderly gastric cancer patients and to evaluate whether there is a difference in the survival of patients with the same LNR (Lymph Node Ratio).Materials and Methods: A total of 222 patients diagnosed with locally advanced gastric cancer and who underwent gastrectomy were included. The patients were divided into two groups according to age. Clinicopathological properties of the two groups were compared. Potential prognostic factors affecting survival were analyzed. Subsequently, the effect of lymphadenectomy and LNR on survival in both groups was evaluated. Results: Significant differences were detected in terms of the location of primary lesions, hemoglobin and albumin levels between elderly patients and non-elderly patients (p < .05). Overall survival (OS) was significantly worse in elderly patients (22 months vs. 67 months, p<0.001). The survival rates in elderly patients were significantly lower from those of non-elderly in the subgroup LNR Stage 2 (12.1% vs. 47.9 %, P = 0.004) and LNR Stage 3 classification (9.1% vs. 34.1%, P = 0.039). LNR was found to be significant for OS with a cut-off point of 0.18. Conclusion: A survival difference was found between the elderly and non-elderly patients with the same LNR. LNR was found to be an independent factor for survival especially in elderly patients. Survival was found to be further decreased in elderly patients compared to non-elderly patients with increasing LNR.


2020 ◽  
Vol 44 (7) ◽  
pp. 2332-2339
Author(s):  
Yuki Ushimaru ◽  
Yukinori Kurokawa ◽  
Tsuyoshi Takahashi ◽  
Takuro Saito ◽  
Kotaro Yamashita ◽  
...  

2012 ◽  
Vol 23 ◽  
pp. ix229
Author(s):  
D. Egamberdiev ◽  
M. Djuraev ◽  
S. Khudayorov ◽  
O. Nematov ◽  
A. Babaev ◽  
...  

2017 ◽  
Vol 28 ◽  
pp. x63
Author(s):  
M. Nakazono ◽  
T. Hayashi ◽  
T. Yamada ◽  
H. Osakabe ◽  
K. Hara ◽  
...  

Chemotherapy ◽  
2012 ◽  
Vol 58 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Xiao Jun Xiang ◽  
Ling Zhang ◽  
Feng Qiu ◽  
Feng Yu ◽  
Zheng Yu Zhan ◽  
...  

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e14515-e14515
Author(s):  
E. Goekkurt ◽  
S. Al-Batran ◽  
L. Obermann ◽  
C. Pauligk ◽  
N. Homann ◽  
...  

e14515 Background: Peripheral neuropathy (PNP) is a dose-limiting side effect of oxaliplatin based chemotherapy. High grade PNP may compromise quality of life especially in elderly patients (pts). A randomized multicenter phase II study was conducted to compare fluorouracil, leucovorin, oxaliplatin with or without docetaxel (FLO vs. FLOT, respectively) in elderly pts with advanced gastric cancer (AGC). Our purpose was to identify pharmacogenetic markers as predictors of high grade PNP within this study. Methods: 143 pts were enrolled in this study. Pts. were numerically >65 years or numerically >59 years but classified biologically >65 years as defined by an Instrumental Activities of Daily Living score of <8. PNP was classified according to an oxaliplatin specific scale. Genotyping was performed using PCR-based RFLP or TaqMan®-based allelic discrimination. 20 polymorphisms in 13 genes being part of the metabolism of the applied drugs or DNA repair were analyzed. Statistical analyses were based on stepwise multivariate cox regression models and included genotypes and clinical parameters. Results: Median age was 71 years (range 60–83). Pts received in median 6 cycles of treatment (range 1–12). 130 pts were evaluable for PN at time of analyses. Of these, 68 received FLO and 62 received FLOT. Cumulative grade 3 PNP occurred in 49% of pts without a significant difference between FLO and FLOT receiving pts (44% and 53%, respectively, p=0.4). Genotypes of TS and MTHFR could be identified as independent risk factors for grade 3 PNP by multivariate analyses. Pts carrying a TS promoter genotype known to be associated with low TS expression (2R/2R, 2R/3RC, 3RC/3RC) were at higher risk for developing grade 3 PNP compared to pts without one of these genotypes (OR 3.0 [95%CI 1.27; 7.06], p=0.01). Pts carrying MTHFR1298AC or CC genotypes were also at higher risk for experiencing grade 3 PNP compared to pts with the wildtype MTHFR-1298AA genotype (OR 3.1 [95%CI 1.26; 7.60], p=0.01). In fact, 89% of pts that experienced grade 3 PNP were carriers of at least one of these risk genotypes. Conclusions: Polymorphisms of TS and MTHFR might be associated with grade 3 PNP in AGC pts receiving oxaliplatin based chemotherapy. No significant financial relationships to disclose.


Sign in / Sign up

Export Citation Format

Share Document